Imperial College London's Centre for Psychedelic Research will begin a government-funded study in October to assess psilocybin-assisted therapy for gambling addiction. The University of Calgary will also launch a clinical trial in October to study the effects of psilocybin paired with Motivational Enhancement Therapy on heavy drinking in patients with Alcohol Use Disorder. In January 2024, a Phase 2 clinical trial will begin to assess the feasibility, safety, and preliminary efficacy of one psilocybin dose to alleviate opioid-refractory pain in advanced cancer patients. This trial will use Filament Health's (OTC:FLHLF) natural psilocybin and is funded by Cy Biopharma and Pancreatic Cancer North America.